Results 51 to 60 of about 241,339 (286)
Role of bone-anabolic agents in the treatment of breast cancer bone metastases [PDF]
, 2014 Skeletal metastases are an incurable complication afflicting the majority of patients who die from advanced breast cancer. They are most often osteolytic, characterized by net bone destruction and suppressed new bone formation. Life expectancy from first
Chirgwin, John M., Suvannasankha, Attaya
core +1 more source
Optimization of PET protocol and interrater reliability of 18F-PSMA-11 imaging of prostate cancer [PDF]
, 2020 Background Several scan parameters for PET imaging with F-18-PSMA-11 such as dosage, acquisition time and scan duration were evaluated to determine the most appropriate scan protocol, as well as the effect of furosemide administration on lesion ...
Achten, Eric +7 more
core +2 more sources
Pediatric Blood &Cancer, EarlyView.ABSTRACT Purpose Chemoimmunotherapy with irinotecan, temozolomide, and dinutuximab (I/T/DIN) has emerged as first‐line therapy for relapsed/refractory (r/r) high‐risk neuroblastoma (HRNB) in North America. Topotecan and cyclophosphamide (T/C) are often used in combination with dinutuximab in the setting of lack of response, progression, or incomplete ...
Benjamin J. Lerman +17 more
wiley +1 more source
Activity of eribulin mesylate in brain metastasis from breast cancer. a stone in a pond? [PDF]
, 2018 Background: Brain metastases develop in approximately 10-25% of patients with metastatic breast cancer (MBC) and are associated with a very poor prognosis.
Catania, G. +5 more
core +1 more source
Pediatric Blood &Cancer, EarlyView.ABSTRACT Background Patients with high‐risk neuroblastoma who either are refractory to induction chemotherapy or relapse following multi‐modal treatment have a dismal prognosis. Based on data from the BEACON trial, since 2021 the UK national guidelines recommend bevacizumab, irinotecan, and temozolomide (BIT) for patients with relapsed/refractory ...
Thomas J. Jackson +20 more
wiley +1 more source
The International Journal of Biological Markers, 1997 The authors evaluate the role of prostate specific antigen (PSA) and bone scintigraphy in the follow-up of radical prostatectomy-treated and radiotherapy-treated patients. 784 patients were evaluated by simultaneous PSA assay and bone scans.
S. Modoni +4 more
doaj +1 more source
Hürthle cell carcinoma: current perspectives. [PDF]
, 2016 Hürthle cell carcinoma (HCC) can present either as a minimally invasive or as a widely invasive tumor. HCC generally has a more aggressive clinical behavior compared with the other differentiated thyroid cancers, and it is associated with a higher rate ...
Ahmadi, Sara +3 more
core +1 more source
Pediatric Blood &Cancer, EarlyView.ABSTRACT Background Alveolar soft part sarcoma (ASPS) is a rare soft tissue sarcoma occurring most commonly in adolescence and young adulthood. Methods We present the clinical characteristics, treatments, and outcomes of patients with newly diagnosed ASPS enrolled on the Children's Oncology Group study ARST0332.
Jacquelyn N. Crane +11 more
wiley +1 more source
A Survival Scoring System for Non-Small Cell Lung Cancer Patients with De Novo Bone Metastases. [PDF]
PLoS ONE, 2016 In the pre-tyrosine kinase inhibitors (TKIs) era, non-small cell lung cancer (NSCLC) patients with de novo bone metastases had a worse prognosis than those without. However, whether epidermal growth factor receptor (EGFR)-TKIs affect the outcomes of EGFR
Yu-Mu Chen +19 more
doaj +1 more source
Cancer Treatment Reviews, 1997 AbstractMetastatic bone disease develops as a result of the many interactions between tumor cells and bone cells. This leads to disruption of normal bone metabolism, with the increased osteoclast activity seen in most, if not all, tumor types providing a rational target for treatment.
openaire +3 more sources